Table 1.
Conventional chemotherapy versus ASCT.
| Author | Patient population (chemotherapy versus ASCT) | Treatment regimen (chemotherapy versus ASCT) | Response (chemotherapy versus ASCT) | Progression-free survival (chemotherapy versus ASCT) | Overall survival (chemotherapy versus ASCT) |
|---|---|---|---|---|---|
| Attal et al.4 | 200 patients <65 years (100 versus 100) | Alternating cycles of VMCP/BVAP × 18# and IFN versus Alternating cycles of VMCP/BVAP × 4–6# and ASCT | 57% versus 81% (p < 0.0001) | 5 years: 10% versus 28% (p = 0.01) | 5 years: 52% versus 12% (p = 0.03) |
| Child et al.5 | 401 patients <65 years (200 versus 201) | ABCM × 4–12# and IFN versus doxorubicin, cyclophosphamide and methyl prednisone × 3# and ASCT | CR: 8% versus 44% (p < 0.0001) | Median: 19.6 m versus 31.6 m (p < 0.0001) | Median: 42.3 m versus 54.1 m (p = 0.04) |
| Blade et al.8 | 164 patients (83 versus 81) | Alternating cycles of VBMCP/VBAD followed by VBMCP/VBAD × 8# versus ASCT | CR: 11% versus 30% (p = 0.002) | Median: 33 m versus 42 m (p = NS) | Median: 66 m versus 61 m (p = NS) |
| Fermand et al.9 | 190 patients 55–65 years (94 versus 96) | VMCP till plateau versus VAMP × 3–4# and ASCT | CR: 20% versus 36% | Median: 19 m versus 25 m (p = 0.07) | Median: 47.6 m versus 47.8 m (p = 0.91) |
| Barlogie et al.10 | 516 patients <70 years (255 versus 261) | VAD × 4# and VBMCP versus VAD × 4# and with/without IFN maintenance | 7 years: 16% versus 17% (p = NS) | 7 years: 42% versus 37% (p = NS) | |
| Palumbo et al.11 | 273 patients <65 years (132 versus 141) | RD × 4# and MPR × 6# versus RD × 4# and ASCT with/without R maintenance | Median: 22.4 m versus 43 m (p < 0.001) | 4 years: 65.3% versus 81.6% (p = 0.02) | |
| Gay et al.12 | 256 patients <65 years (129 versus 127) | RD × 4# and RCD × 6# versus RD × 4# and ASCT with/without R maintenance | Median: 28.6 m versus 43.3 m (p < 0.0001) | 4 years: 73% versus 86% (p = 0.004) |
ABCM, adriamycin; ASCT, autologous stem-cell transplant; BCNU, cyclophosphamide and melphalan; BVAP, BCNU, vincristine, adriamycin, prednisone; CR, complete response; IFN, interferon; MPR, melphalan, prednisolone, revilimid; NS, nonsignificant; R, revilimid; RCD, revilimid, cyclophosphamide, dexamethasone; RD, revilimid, dexamethasone; VAD, vincristine, adriamycin, dexamethasone; VAMP, vincristine, adriamycin, melphalan, prednisolone; VBAD, vincristine, BCNU, adriamycin, dexamethasone; VMCP, vincristine, melphalan, cyclophosphamide, prednisolone; VBMCP, vincristine, carmustine, melphalan, cyclophosphamide, prednisone.